ASX:CYC

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Cyclopharm Limited engages in the research and development, manufacture, and sale of medical equipment and radiopharmaceuticals in the Asia Pacific, Europe, Canada, and internationally. More Details


Snowflake Analysis

Excellent balance sheet with reasonable growth potential.

Share Price & News

How has Cyclopharm's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: CYC is more volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 15% a week.

Volatility Over Time: CYC's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of Australian stocks.


Market Performance


7 Day Return

7.0%

CYC

-2.2%

AU Medical Equipment

1.3%

AU Market


1 Year Return

100.0%

CYC

5.4%

AU Medical Equipment

-1.7%

AU Market

Return vs Industry: CYC exceeded the Australian Medical Equipment industry which returned 5.4% over the past year.

Return vs Market: CYC exceeded the Australian Market which returned -1.7% over the past year.


Shareholder returns

CYCIndustryMarket
7 Day7.0%-2.2%1.3%
30 Day13.3%3.4%10.4%
90 Day66.7%12.0%8.8%
1 Year101.9%100.0%6.7%5.4%1.7%-1.7%
3 Year136.4%130.0%32.7%26.8%23.1%7.9%
5 Year329.7%303.5%117.7%101.4%57.2%26.0%

Long-Term Price Volatility Vs. Market

How volatile is Cyclopharm's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Cyclopharm undervalued compared to its fair value and its price relative to the market?

44.5%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: CYC (A$2.3) is trading below our estimate of fair value (A$4.15)

Significantly Below Fair Value: CYC is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: CYC is unprofitable, so we can't compare its PE Ratio to the AU Medical Equipment industry average.

PE vs Market: CYC is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CYC's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CYC is overvalued based on its PB Ratio (10.7x) compared to the AU Medical Equipment industry average (6.9x).


Next Steps

Future Growth

How is Cyclopharm forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

112.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CYC is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.3%).

Earnings vs Market: CYC is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: CYC's is expected to become profitable in the next 3 years.

Revenue vs Market: CYC's revenue (18% per year) is forecast to grow faster than the Australian market (5.1% per year).

High Growth Revenue: CYC's revenue (18% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if CYC's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Cyclopharm performed over the past 5 years?

-74.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CYC is currently unprofitable.

Growing Profit Margin: CYC is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: CYC is unprofitable, and losses have increased over the past 5 years at a rate of 74.8% per year.

Accelerating Growth: Unable to compare CYC's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CYC is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (41.9%).


Return on Equity

High ROE: CYC has a negative Return on Equity (-32.59%), as it is currently unprofitable.


Next Steps

Financial Health

How is Cyclopharm's financial position?


Financial Position Analysis

Short Term Liabilities: CYC's short term assets (A$15.6M) exceed its short term liabilities (A$5.6M).

Long Term Liabilities: CYC's short term assets (A$15.6M) exceed its long term liabilities (A$5.7M).


Debt to Equity History and Analysis

Debt Level: CYC is debt free.

Reducing Debt: CYC has no debt compared to 5 years ago when its debt to equity ratio was 2.5%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CYC has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if CYC has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Cyclopharm current dividend yield, its reliability and sustainability?

0.43%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: CYC's dividend (0.43%) isn’t notable compared to the bottom 25% of dividend payers in the Australian market (2.05%).

High Dividend: CYC's dividend (0.43%) is low compared to the top 25% of dividend payers in the Australian market (5.06%).


Stability and Growth of Payments

Stable Dividend: CYC is not paying a notable dividend for the Australian market, therefore no need to check if payments are stable.

Growing Dividend: CYC is not paying a notable dividend for the Australian market, therefore no need to check if payments are increasing.


Current Payout to Shareholders

Dividend Coverage: CYC is not paying a notable dividend for the Australian market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CYC's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.2yrs

Average management tenure


CEO

James McBrayer (55 yo)

12.42yrs

Tenure

AU$753,361

Compensation

Mr. James S. McBrayer,, BSPharm, GDM, FAICD, AIM, has been the Managing Director at Cyclopharm Ltd. since June 3, 2008 and also serves as its Chief Executive Officer. Mr. McBrayer has been Company Secretar...


CEO Compensation Analysis

Compensation vs Market: James's total compensation ($USD556.93K) is above average for companies of similar size in the Australian market ($USD282.32K).

Compensation vs Earnings: James's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
James McBrayer
CEO, MD12.42yrsAU$753.36k6.37%
A$ 11.8m
Mathew Farag
Chief Operating Officer3.83yrsAU$368.55k0.90%
A$ 1.7m
Graham Phillips
Finance Managerno dataAU$152.73kno data
Mark Doverty
Global Head of Regulatory Compliance & Clinical Research1.17yrsno datano data
Sally-Ann Cornelius
Head of Sales1.17yrsno datano data
Niamh McAree
Head of Quality and Regulatory1.17yrsno datano data
Chris Quinn
Head of Service1.17yrsno datano data
Sui Cheah
Financial Controller9.67yrsAU$64.44kno data
Lynn McLauchlin
General Manager of Canadano dataAU$173.42kno data
Bjorn Altmann
General Manager of Europeno dataAU$156.78kno data
Gary Somerville
Quality & Regulatory Managerno dataAU$151.96kno data
Charles Buttigieg
Sales & Marketing Manager - Australiano dataAU$207.42kno data

1.2yrs

Average Tenure

Experienced Management: CYC's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
James McBrayer
CEO, MD12.42yrsAU$753.36k6.37%
A$ 11.8m
David Heaney
Independent Non-Executive Chairman3.58yrsAU$72.71k0.29%
A$ 533.6k
Thomas McDonald
Independent Non-Executive Director3.58yrsAU$51.94k0.054%
A$ 99.4k

3.6yrs

Average Tenure

Experienced Board: CYC's board of directors are considered experienced (3.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: CYC insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 16.5%.


Top Shareholders

Company Information

Cyclopharm Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Cyclopharm Limited
  • Ticker: CYC
  • Exchange: ASX
  • Founded: 1986
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: AU$184.631m
  • Shares outstanding: 80.27m
  • Website: https://www.cyclopharm.com.au

Number of Employees


Location

  • Cyclopharm Limited
  • 1 The Crescent
  • Unit 4
  • Kingsgrove
  • New South Wales
  • 2208
  • Australia

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CYCASX (Australian Securities Exchange)YesOrdinary SharesAUAUDJan 2007
CYCCHIA (Chi-X Australia)YesOrdinary SharesAUAUDJan 2007

Biography

Cyclopharm Limited engages in the research and development, manufacture, and sale of medical equipment and radiopharmaceuticals in the Asia Pacific, Europe, Canada, and internationally. The company operate...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/11/29 07:05
End of Day Share Price2020/11/27 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.